AXO-Lenti-PD

ProSavin®, a dopamine gene therapy for advanced Parkinson’s disease: 6 years phase I/II clinical update

Palfi, et al. Poster presented at ESGCT 2018

Long-Term Follow-Up of a Phase I/II Study of ProSavin, a Lentiviral Vector Gene Therapy for Parkinson’s Disease

Palfi, et al. Hum Gene Ther Clin Dev. 2018 Sep;29(3):148-155.

Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson’s disease: a dose escalation, open-label, phase 1/2 trial

Palfi, et al. Lancet. 2014 Mar 29;383(9923):1138-46

AXOVANT GENE THERAPIES

Eleven Times Square, 33rd Floor
New York, NY 10036
United States

+1-833-AXOVANT (1-833-296-8268)

  • Axovant Gene Therapies LinkedIn
  • Axovant Gene Therapies Twitter
  • Axovant Gene Therapies Facebook

AXOVANT SCIENCES GMBH

Viaduktstrasse 8
4051 Basel
Switzerland